To confirm the effect of Young Barley Leaf Powder (YBLP) on hypercholesterolemia, we performed a preclinical study involving diet-induced hypercholesterolemia in rats and a clinical study in healthy subjects. The preclinical study used three experimental groups : Wistar rats were fed a normal diet, a high cholesterol diet (HCD), or a HCD with 4 % (w/w) YBLP for 4 weeks. In the clinical study, fifteen healthy subjects, with mean total plasma cholesterol of 205.1 mg/dL, were supplemented with a powdered drink containing YBLP for 12 weeks. The clinical study was of a preliminary open-label design. Following treatment, lipid parameters were analyzed in the rat and human plasma. The results indicated that total plasma cholesterol and LDL cholesterol were decreased, in both the pre-clinical and clinical studies, following ingestion of YBLP. Additionally, the ability of YBLP to absorb bile acids was examined. YBLP, and residual substances after hexane extraction, were observed to strongly absorb bile acids. These results suggest that YBLP could improve hypercholesterolemia due to its ability to absorb bile acids.

